Financial Results for Full Year 2007: NicOx Significantly Advances Clinica...( compared to 64 people on December 31200...),Health
| HOME >> MEDICINE >> TECHNOLOGY |
, compared to 64 people on December 31, 2006.
Administrative and selling expenses amounted to euro 11.3 million in 2007, compared to euro 7.7 million in 2006. General and administrative expenses were euro 3.2 million in 2007 and were primarily the result of personnel expenses in administrative and financial functions, as well as the remuneration of corporate officers, including stock option, gratuitous share and warrant attributions. These expenses also included structural costs such as leases, property service charges, and maintenance costs (excluding structural costs related to research and development activities), legal and accounting fees and other external administrative costs.
Selling expenses, which reached euro 8.1 million in 2007, were the result of market analysis activities for naproxcinod, as well as business development and communication activities. The increase in selling expenses is also due to the hiring of new personnel following the creation, in 2007, of a commercial department whose primary function is to develop commercial strategies for NicOx' product portfolio. On December 31, 2007, the Company employed 33 people in selling, general, and administrative departments, compared to 25 people on December 31, 2006.
Operating loss
The operating loss amounted to euro 37.2 million in 2007, compared to euro 26.7 million in 2006. This increase results primarily from the strong increase in operating expenses as indicated above.
Other results
Net financial income amounted to euro 5.2 million in 2007, compared to euro 2.2 million in 2006. Net financial income has benefited from the increase in the Company's cash, cash equivalents, and financial instruments following the capital increase completed in February 2007.
The income tax expense incurred by NicOx in 2007 relates principally to its Italian subsidiary and amounts to euro 0.1 million compared to euro 0.3 million in 2006.
Net loss
The net loss
'/>"/>
| SOURCE NicOx S.A. Copyright©2008 PR Newswire. All rights reserved |
Related medicine technology :
1. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
2. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
3. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
4. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
5. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
6. Progen Pharmaceuticals Announces Fiscal 2007 Financial Results
7. Biopure Announces 2007 Third Quarter Financial Results
8. Xytis Names Gordon H. Busenbark as Chief Financial Officer
9. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
10. Pharmacopeia Announces Third Quarter 2007 Financial Results
11. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |